uk
us
de
Scibase
  • APPLICATIONS
    • MELANOMA
    • KERATINOCYTE CANCER
    • SKIN BARRIER ASSESSMENT
  • EIS TECHNOLOGY
    • HOW TO MEASURE
    • CLINICAL STUDIES
    • PUBLICATIONS
    • RESEARCH MILESTONES
  • FOR PATIENTS
    • WHY NEVISENSE?
    • FIND CLINICS
    • SKIN CANCER INFORMATION
    • SELF EXAMINATION
    • PATIENT ORGANIZATIONS
  • SCIBASE
    • ABOUT SCIBASE
    • AVAILABLE MARKETS
    • NEWS & EVENTS
    • WE ARE SCIBASE
    • CAREERS
    • CEO-LETTERS
  • INVESTORS
  • CONTACT US
  • APPLICATIONS
    • MELANOMA
    • KERATINOCYTE CANCER
    • SKIN BARRIER ASSESSMENT
  • EIS TECHNOLOGY
    • HOW TO MEASURE
    • CLINICAL STUDIES
    • PUBLICATIONS
    • RESEARCH MILESTONES
  • FOR PATIENTS
    • WHY NEVISENSE?
    • FIND CLINICS
    • SKIN CANCER INFORMATION
    • SELF EXAMINATION
    • PATIENT ORGANIZATIONS
  • SCIBASE
    • ABOUT SCIBASE
    • AVAILABLE MARKETS
    • NEWS & EVENTS
    • WE ARE SCIBASE
    • CAREERS
    • CEO-LETTERS
  • INVESTORS
  • CONTACT US
uk
us
de

Leading developer of augmented intelligence-based solutions for skin disorders

50. DDG-Tagung, 2019

  • The Nevisense product
    • How it works
    • How to measure
    • The EIS Technology
    • Clinical studies
    • Clinical benefits
    • Publications
    • Barrier Research
    • Skin Barrier Assessment
  • For patients
    • Skin cancer information
    • Why Nevisense?
    • Find clinics
    • Self examination
    • Patient organizations
  • Scibase
    • About Scibase
    • We are Scibase
    • News and events
    • Contact us
    • Privacy and Cookie policy
    • Login
  • Investors
    • About Scibase
    • Press releases
    • Business model
    • Reports and presentations
    • Corporate Governance
    • Contact